GlassScriptPhysician profile
Iris E Gonzalo-Sowle
NPI 1154783439
$3,414.55
in general payments reported to CMS, 2019-2025
23 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $396 · 2022: $496 · 2023: $757 · 2024: $696 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,521.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $361.50 | 2021-2024 | Invega Sustenna, Invega Trinza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $334.63 | 2025 | |
| Sanofi-Aventis U.S. LLC | $258.62 | 2021-2023 | |
| Novo Nordisk INC | $249.99 | 2022-2023 | Wegovy |
| Medtronic, INC. | $156.07 | 2021-2022 | |
| Madrigal Pharmaceuticals | $134.85 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $131.53 | 2025 | Wavewriter Alpha Prime 16 |
| Alexion Pharmaceuticals, INC. | $131.08 | 2025 | |
| Ucb, INC. | $127.92 | 2025 | Rystiggo |
| Viatris Specialty LLC | $125.00 | 2025 | Yupelri |
| Abiomed | $124.96 | 2024 | Impella |
| Astellas Pharma US INC | $124.65 | 2024 | Veozah |
| Abbvie INC. | $124.20 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $119.93 | 2023 | Crysvita |
| Neurocrine Biosciences, INC. | $118.02 | 2023 | Ingrezza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $114.30 | 2023 | Krystexxa |
| Axsome Therapeutics, INC. | $107.40 | 2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $105.12 | 2024 | Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $104.08 | 2021 | |
| Alkermes, INC. | $101.91 | 2023 | |
| Jazz Pharmaceuticals INC. | $95.95 | 2022 | |
| Eisai INC. | $83.40 | 2025 | |
| Neurelis, INC. | $79.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iris Gonzalo-Sowle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.